Effects of Kami Guibi-tang in patients with mild cognitive impairment: study protocol for a phase III, randomized, double-blind, and placebo-controlled trial

BMC Complementary Medicine and Therapies

Study Protocol

Woo-Sang Jung¹  Seungwon Kwon¹  Sang-Kwan Moon¹  Hye-Min Heo²  Tae-Bin Yim²  Hee-Yeon Shin³  Geon-Ho Jahng⁴  Seung-Yeon Cho⁵  Jung-Mi Park⁵  Seong-Uk Park⁵  Chang-Nam Ko⁵ 

[1]Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, 02447, Seoul, Republic of Korea

[2]Department of Clinical Korean Medicine, Graduate School, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, 02447, Seoul, Republic of Korea

[3]Stroke and Neurological Disorders Center, Kyung Hee University Hospital at Gangdong, 892, Dongnam-ro, Gangdong-gu, 05278, Seoul, Republic of Korea

[4]Department of Internal Korean Medicine, Korean Medicine Center, CHA university Bundang Medical Center, 59, Yatap-ro, Bundang-gu, 13496, Seongnam-si, Gyeonggi-do, Republic of Korea

[5]Department of Clinical Korean Medicine, Graduate School, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, 02447, Seoul, Republic of Korea

[6]Department of Radiology, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, 892, Dongnam-ro, Gangdong-gu, 05278, Seoul, Republic of Korea

[7]Stroke and Neurological Disorders Center, Kyung Hee University Hospital at Gangdong, 892, Dongnam-ro, Gangdong-gu, 05278, Seoul, Republic of Korea

[8]Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, 02447, Seoul, Republic of Korea

关键词: Mild cognitive impairment (MCI);    Amnestic mild cognitive impairment (aMCI);    Kami Guibi-tang;    Herbal medicine;    Herbal formula;    Korean medicine;    Neuropsychological test;    Functional magnetic resonance imaging (fMRI);   

DOI  :  10.1186/s12906-022-03805-9

 received in 2022-04-25, accepted in 2022-11-21,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundAmnestic mild cognitive impairment (aMCI) is often considered a precursor to Alzheimer’s disease (AD) and represents a key therapeutic target for early intervention of AD. However, no treatments have been approved for MCI at present. Our previous pilot study has shown that Kami Guibi-tang (KGT), a traditional herbal prescription widely used in Korean medicine for treating amnesia, might be beneficial for improving general cognitive function of aMCI patients. We will conduct a larger-scale clinical trial to validate the findings of our pilot study and further examine the efficacy and safety of KGT in aMCI.MethodsThis trial is designed as a randomized, double-blind, placebo-controlled clinical trial. A total of 84 aMCI patients will be recruited and randomized into the treatment and control groups. Participants will be administered either KGT or placebo granules for 24 weeks, with a follow-up period of 12 weeks after the last treatment. Primary outcomes will include changes in cognitive performance assessed using a neuropsychological test battery, called the Seoul Neuropsychological Screening Battery, between the baseline, post-intervention visit, and follow-up visit (24th and 36th week, respectively). Secondary outcomes will involve the rate of progression to AD, changes in neuroimaging signals assessed using structural magnetic resonance imaging (MRI), resting-state functional MRI (rs-fMRI), and task-based fMRI, and changes in blood biomarkers measured by the ratio of plasma amyloid-β 42/40 levels (Aβ42/Aβ40) between the baseline and post-intervention visit (24th week). For safety assessments, blood chemistry tests and electrocardiograms (ECG) will also be performed.DiscussionThis study aims to provide confirmatory evidence of the effect of the Korean herbal medicine, KGT, on improving cognitive function in patients with aMCI. We will identify the possible mechanisms underlying the effects of KGT using neuroimaging signals and blood biomarkers.Trial registrationKorean Clinical Trial Registry (https://cris.nih.go.kr/cris/search/detailSearch.do/16918; Registration number: KCT0007039; Date of registration: February 24, 2022).

【 授权许可】

CC BY   
© The Author(s) 2022

【 图 表 】

Fig. 2

12936_2022_4386_Article_IEq142.gif

Fig. 1

Fig. 5